Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
מאת: Nutman A., Lellouche J., Temkin E., Daikos G., Skiada A., Durante-Mangoni E., Dishon-Benattar Y., Bitterman R., Yahav D., Daitch V., Bernardo M., Iossa D., Zusman O., Friberg L.E., Mouton J.W., Theuretzbacher U., Leibovici L., Paul M., Carmeli Y., Benattar Y.D., Dickstein Y., Zayyad H., Koppel F., Zak-Doron Y., Altunin S., Andria N., Neuberger A., Stern A., Petersiel N., Raines M., Karban A., Eliakim-Raz N., Elbaz M., Atamna H., Babich T., Adler A., Levi I., Daikos G.L., Pavleas I., Antoniadou A., Kotsaki A., Andini R., Cavezza G., Bertolino L., Giuffre G., Giurazza R., Cuccurullo S., Galdo M., Murino P., Cristinziano A., Corcione A., Zampino R., Pafundi P.C., Mouton J., Friberg L., Kristoffersson A., AIDA Study Group
פורסם ב: Clinical Microbiology and Infection
תיאור: Objectives: In vitro models showing synergism between polymyxins and carbapenems support combination treatment for carba המשך…